If the results of this study extend to human patients, this dietary supplement could become a staple in the treatment of hyperlipidemia, type-2 diabetes, and perhaps metabolic syndrome.
"It is a fascinating find. We show the mechanism by which naringenin increases two important pharmaceutical targets, PPARa and PPAR?, while blocking a third, LXRa. The results are similar to those induced by long periods of fasting,” said Yaakov Nahmias, of the Hebrew University of Jerusalem the paper's senior author.
The report appears in this week issue of the online journal PLoS ONE.